حول Glycomine
Company Overview
Glycomine is a small clinical stage bio tech company committed to developing therapeutics for[RM1] congenital disorders of glycosylation (CDG), serious rare diseases for which the vast majority of which do not have any disease-modifying treatment options available. Many of these diseases are driven by a genetic mutation that disrupts the function of an important enzyme. Glycomine’s lead clinical program in PMM2-CDG aims to deliver a substrate to bypass the enzymatic problem.
Our team has a special dedication to find solutions to the significant unmet medical need experienced by patients and families with rare diseases. We come from many disciplines and bring multiple viewpoints and broad expertise to our mission. We are driven by the imperative and the opportunity to develop therapies that can provide meaningful improvements in the quality of life for patients, caregivers, and families.
